Company Comparison
BioPharma Nexus vs 23andMe
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | BioPharma Nexus | 23andMe |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | Cambridge | South San Francisco, California |
| Founded | — | 2006 |
| Status | Active | Active |
| Last Funding Stage | Pre-Seed | — |
| Total Funding | $2.8M | — |
| Valuation | — | — |
What They Build
BioPharma Nexus
An early-stage Cambridge biotech company serving as a nexus in the biopharmaceutical industry with $2.8M pre-seed funding.
23andMe
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.
Key Investors
BioPharma Nexus
No investors listed.
Sector Overlap
Both BioPharma Nexus and 23andMe operate in Biotech.
Browse all Biotech companies →Websites
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Now in alpha with select funds. 14-day trial available.